1. Home
  2. RIGL vs QUAD Comparison

RIGL vs QUAD Comparison

Compare RIGL & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • QUAD
  • Stock Information
  • Founded
  • RIGL 1996
  • QUAD 1971
  • Country
  • RIGL United States
  • QUAD United States
  • Employees
  • RIGL N/A
  • QUAD N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • QUAD Publishing
  • Sector
  • RIGL Health Care
  • QUAD Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • QUAD Nasdaq
  • Market Cap
  • RIGL 335.5M
  • QUAD 304.4M
  • IPO Year
  • RIGL 2000
  • QUAD 2010
  • Fundamental
  • Price
  • RIGL $37.96
  • QUAD $6.60
  • Analyst Decision
  • RIGL Buy
  • QUAD Strong Buy
  • Analyst Count
  • RIGL 5
  • QUAD 2
  • Target Price
  • RIGL $38.20
  • QUAD $9.30
  • AVG Volume (30 Days)
  • RIGL 761.5K
  • QUAD 233.0K
  • Earning Date
  • RIGL 11-06-2025
  • QUAD 10-27-2025
  • Dividend Yield
  • RIGL N/A
  • QUAD 4.55%
  • EPS Growth
  • RIGL N/A
  • QUAD N/A
  • EPS
  • RIGL 5.43
  • QUAD N/A
  • Revenue
  • RIGL $267,921,000.00
  • QUAD $2,584,500,000.00
  • Revenue This Year
  • RIGL $59.93
  • QUAD N/A
  • Revenue Next Year
  • RIGL N/A
  • QUAD N/A
  • P/E Ratio
  • RIGL $6.99
  • QUAD N/A
  • Revenue Growth
  • RIGL 105.62
  • QUAD N/A
  • 52 Week Low
  • RIGL $12.76
  • QUAD $4.27
  • 52 Week High
  • RIGL $43.72
  • QUAD $9.13
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 56.17
  • QUAD 55.83
  • Support Level
  • RIGL $35.56
  • QUAD $6.42
  • Resistance Level
  • RIGL $42.65
  • QUAD $6.69
  • Average True Range (ATR)
  • RIGL 2.19
  • QUAD 0.21
  • MACD
  • RIGL -1.00
  • QUAD -0.02
  • Stochastic Oscillator
  • RIGL 32.70
  • QUAD 44.55

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About QUAD Quad Graphics Inc

Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..

Share on Social Networks: